Clinical Trial Update: A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive [Phase 2]

View source ↗

Summary

A Phase 2 multicenter randomized trial evaluating an interventional treatment for operable stage II–III non-small cell lung cancer with minimal residual disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: DFS | Phase 2 | Status: NOT_YET_RECRUITING